Oncolytics Biotech® and SOLTI Achieve Primary Endpoint in AWARE-1 Study
(NASDAQ: ONCY) (TSX: ONC), together with SOLTI, recently announced new clinical data from the AWARE-1 window-of-opportunity breast cancer study showing patients receiving pelareorep plus checkpoint blockade therapymet the trial\'s primary endpoint.
- (NASDAQ: ONCY) (TSX: ONC), together with SOLTI, recently announced new clinical data from the AWARE-1 window-of-opportunity breast cancer study showing patients receiving pelareorep plus checkpoint blockade therapymet the trial\'s primary endpoint.
- "\nMatt Coffey, Ph.D., M.B.A., President and Chief Executive Officer of Oncolytics Biotech Inc. added, "Achieving the primary endpoint in AWARE-1 is a key milestone validating our clinical development strategy.
- The primary endpoint of the study is overall CelTIL score (a measurement of cellularity and tumor-infiltrating lymphocytes).
- It is unknown whether and how Oncolytics may be affected if the COVID-19 pandemic persists for an extended period of time.